Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the successful completion of the manufacturing for CHM 2101 research-grade plasmids.
The company said this is a critical first step in the development of its CDH17 CAR-T.
The manufacturing of CAR-T therapies is dependent upon plasmids and viral vectors that hold the genetic instructions for each specific product. Plasmids are small DNA molecules that carry genetic instructions and their successful manufacture marks an important early step for all CAR T therapies.
"In collaboration with the University of Pennsylvania, all of the research-grade helper and transfer plasmids for the CDH17 CAR-T have been completed and released," said the company.
"The achievement of this first step in CAR-T manufacturing enables progression to research vector manufacturing, GMP plasmid and vector manufacturing and advancement of technical operations in readiness for the CDH17 CAR-T phase 1 clinical trial."
“We are very pleased that we have been able to achieve this key first step so rapidly after licensing. This accomplishment speaks to the commitment and drive that the Chimeric and University of Pennsylvania teams share to move this important CAR T forward to Phase 1 clinical trials,” said Chimeric CEO and managing director Jennifer Chow.
The company said it is also progressing its CLTX CAR-T Phase 1 clinical trial in glioblastoma (brain cancer) at The City of Hope Cancer Centre in California.
